Apotex Builds Momentum in Canada's Biosimilar Market After World's First Approval
Jun 1, 2018Health Canada Leads the Way by Approving the First-Ever Pegfilgrastim Biosimilar in any Highly Regulated World Market
Toronto, ON, June 1st - 2018 - Apobiologix, a division of Apotex Inc., further bolstered its leadership in Canada’s growing biosimilar market. The company that is focused on the development of biosimilars for global markets, recently received approval from Health Canada for Apobiologix’s latest product addition, LapelgaTM.
The recent Health Canada approval is a noteworthy success for Apobiologix as this is the first-ever pegfilgrastim biosimilar approved in any highly regulated market worldwide.
Apobiologix successfully launched its first product, Grastofil (filgrastim) in Canada in March, 2016. Since that time, Grastofil has delivered significant cost savings to the Canadian healthcare system.
“Biosimilars provide an opportunity for the sustainability of global healthcare systems by increasing competition and reducing costs, and very importantly, giving patients increased access to highly effective and often lifesaving biological drugs,” said Dr. Klaus Martin, President, Apobiologix.
Biosimilars are designed to be similar to an existing biologic drug. Biologic drugs come from living organisms or from their cells and are often made using biotechnology. LapelgaTM encourages the body’s production of white blood cells which helps to fight infection in patients undergoing certain cancer treatments, such as chemotherapy and radiation.
According to Evaluate Pharma 2017 and IMSQuintiles, 2017, IQVIA “2018 and beyond” report, the global biologics market is expected to reach more than $325 billion in 2022 with 13 of 20 top-selling drugs being biologics.
###
Jordan Berman
Global Director, Corporate Communications
Apotex Inc.
Direct: 416-401-7487
Mobile: 647-272-2287
Email
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 9, 2026
Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.
-
Oct 5, 2026
Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, October 5, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today the closing of the previously announced offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Offering was made through a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.
-
Sep 29, 2026
Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, September 28, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Notes are being offered on an agency basis by a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.